Podcasts about atopic

Atopic eczema is the most common form of the disease among New Zealanders. New findings by a team of scientists from the NIH indicate two particular chemicals are responsible for triggering eczema in many cases - and these chemicals are likely hidden in our own homes.

Lebrikizumab for AD -JAKi's for TEN -Dupi can stop the atopic march -Acne scarring: What to do (part 2) -Want to donate to the cause? Do so here!Donate to the podcast: uofuhealth.org/dermasphereCheck out our video content on YouTube:www.youtube.com/@dermaspherepodcastand VuMedi!: www.vumedi.com/channel/dermasphere/The University of Utah's DermatologyECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -⁠ Connect with us!- Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC- Instagram: dermaspherepodcast- Facebook: www.facebook.com/DermaspherePodcast/- Check out Luke and Michelle's other podcast,SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out ourfriends at:- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learnmore dermatology!

In this episode of Derms and Conditions, host James Del Rosso, DO, welcomes David Cotter, MD, a dermatologist in clinical practice and assistant clinical professor at the University of Nevada Las Vegas School of Medicine, to discuss the integral role of patch testing in managing atopic dermatitis (AD) and allergic contact dermatitis (ACD), providing practical insights on incorporating patch testing into practice and differentiating between these often-overlapping conditions. They begin with Dr Cotter highlighting the importance of a holistic approach when evaluating patients with AD and ACD. A thorough history and physical examination, combined with a detailed understanding of allergen exposure, are essential for tailoring patch testing to the patient's specific needs. He notes that AD and ACD frequently coexist, and identifying an allergen component is particularly valuable in cases of treatment-resistant AD or when new patterns, such as hand or facial dermatitis, emerge. For patients already on systemic therapies like biologics and JAK inhibitors, interpreting patch test results requires careful consideration. While biologics may control aspects of ACD, breakthrough dermatitis often signals clinically relevant allergens. Patch testing can be performed without discontinuing current biologic or JAK inhibitor therapy, though a washout period and repeat testing may sometimes be needed. Dr Cotter shares that patch testing can significantly improve outcomes, especially for patients who prefer allergen avoidance over additional systemic therapies. Tools like allergen-detection apps can empower patients to avoid triggers in their daily lives. When avoidance is not feasible, oral JAK inhibitors approved for AD can also help manage both AD and ACD symptoms in many cases. Tune in to the full episode to explore the value of patch testing in modern dermatology and get actionable strategies to improve care for patients with complex dermatitis cases.

Atopic dermatitis is the single most common chronic condition in the world, but it's also the most misunderstood and mistreated. People who struggle with it endure years of discomfort, a drop in their quality of life, a revolving door of doctors, reams of blood tests and a multitude of treatments. These treatments often focus on food and finding out what they can stop eating to get better. Though this is well-intentioned advice, it is misguided. The food you eat isn't the root cause of eczema. Growing data show that eczema is what causes food allergies. This changes everything about how eczema is treated, and also how to prevent it in infants. For high-risk babies, early and frequent exposure to food can significantly reduce the chance of atopic dermatitis and potentially set them up for an allergy-free life. In this episode, I'm joined by the Chief Medical Officer at Snö Asthma & Allergy, Dr. Stuart Carr. He shares the truth about atopic dermatitis, and why there are more treatment options on the table other than avoiding certain foods and hoping for the best.  Things You'll Learn In This Episode  -Sensitization vs. true allergy  Food sensitivity and allergy are two very different things that often get mixed up. How do doctors determine if you're allergic to something? -The right way to restrict your diet  Many people use elimination diets to try and combat allergies. How do you do this without actually increasing your chance of allergy? -Early and often exposure is key Parents of infants prone to eczema often delay the introduction of certain foods, could this actually make the likelihood of allergy higher? -Food in mouth, but not on skin Atopic dermatitis patients think eating certain foods will trigger a reaction. What actually triggers a reaction?  Guest Bio Dr. Carr has been Chief Medical Officer at Snö Asthma & Allergy in Abu Dhabi since January 2019, having spent the previous 20 years in academic clinical allergy practice in Edmonton, Canada.  He was an Associate Clinical Professor at the University of Alberta, and is also a Past-President of the Canadian Society of Allergy and Clinical Immunology, and a reviewer for Allergy, Asthma & Clinical Immunology, the journal of the CSACI. His primary interests are pediatric asthma, food allergy, and eosinophilic esophagitis, and Dr. Carr is currently involved in a Canada-wide collaboration examining the safety and effectiveness of oral immunotherapy for peanut and other food allergies in preschool children. To learn more follow @allergydoc4kidz on Instagram   About Your Host Hosted by Dr. Deepa Grandon, MD MBA, triple board-certified physician with over 23 years of experience working as a Physician Consultant for influential organizations worldwide. Dr. Grandon is the founder of Transformational Life Consulting (TLC) and an outspoken faith-based leader in evidenced-based lifestyle medicine.   ​​TLC is presenting this podcast as a form of information sharing only. It is not medical advice or intended to replace the judgment of a licensed physician. TLC is not responsible for any claims related to procedures, professionals, products, or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services, or methods that might be referenced. Check out this episode on our website, Apple Podcasts, or Spotify, and don't forget to leave a review if you like what you heard. Your review feeds the algorithm so our show reaches more people. Thank you!

Join us as we go through the JEADV Editor's Picks of October 2024:   (1) Medical complications of tattoos: prevention and regulation (2) Looking behind the curtain: Onychoscopy of the nail unit (3) Melanoma in adolescents and young adults: increasing incidence and specific features (4) Atopic dermatitis in adults and resistance to dupilumab: searching for T-cell clonality   Read the Editor's Picks here: https://onlinelibrary.wiley.com/doi/10.1111/jdv.19205   Link to video version: https://youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1&si=FEwX-Otytpxs7Ab3   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/  

Are you curious about how biologic medications are transforming the treatment of asthma, eczema, allergies, and more? Dr. Perdita Permaul joins Dr. Gupta and Kortney to discuss the available biologic medications for allergic conditions. We walk through the eight biologics currently available for allergic diseases, explaining how these medications target different parts of the immune system to treat allergic conditions more effectively than traditional medications. Dr. Permaul explains how biologics have evolved since 2003 and how they are changing the way allergic conditions are treated. She also explains why some of the biologics treat multiple diseases, whereas some are only approved for one.  What we cover in our episode about the available biologics for allergic conditions How biologics work for allergic conditions: We unpack how biologic medications target specific parts of the immune system, reducing inflammation and improving the quality of life for patients with allergic diseases. History and evolution of biologics: Dr. Permaul walks us through the timeline of biologics, starting with Xolair in 2003 and how these treatments have expanded to target other conditions over time. Which biologics treat which conditions: From asthma and eczema to food allergies and nasal polyps, we break down which biologics are available and how they help patients with allergic conditions. Future of biologics: Dr. Permaul discusses the potential of biologics to be used for more conditions in the future, including ongoing research into food allergy treatments. Biologics Cheat Sheet Below is a list of the 8 biologics discussed in this episode. We have briefly outlined their mechanism of action along with the approved conditions and ages the drug is available for presecription.  Omalizumab (Xolair) Xolair works by binding to IgE to prevent allergic reactions. It has since been approved for chronic hives, nasal polyps, and food allergies. Allergic asthma: 6+ Chronic idiopathic urticaria (hives: 12+ Chronic rhinosinusitis with nasal polyps (CRSwNP): 18+ Food allergies:1+ Mepolizumab (Nucala) Targets and blocks interleukin-5 (IL-5) play a key role in the activation and priming of eosinophils, a type of white blood cell that causes inflammation in asthma. Eosinophilic Asthma: 6+ CRSwNP: 18+ Eosinophilic Granulomatosis with Polyangiitis (EGPA): 18+ Hypereosinophilic Syndrome: ≥6 months Reslizumab (Cinqair) Targets and blocks interleukin-5 (IL-5). Eosinophilic asthma: 18+ Benralizumab (Fasenra) Binds to the IL-5 receptor, preventing eosinophils from growing and causing inflammation. Eosinophilic asthma: 6+ Eosinophilic Granulomatosis with Polyangiitis (EGPA): 18+ Dupilumab (Dupixent) Targets and blocks IL-4 and IL-13 to reduce inflammation Asthma: 6+ Atopic Dermatitis: 6 months+ CRSwNP: 18+ Eosinophilic Esophagitis (EoE): 1+ (> 33 lbs) Approved for prurigo nodularis (PN): 18+ Tezepelumab (Tezspire) Blocks thymic stromal lymphopoietin (TSLP). Asthma: 12+ Tralokinumab (Adbry, Adtralza) Targets and neutralizes interleukin-13 (IL-13). Atopic dermatitis: 12+ Lebrikizumab (Ebglyss) Targets and neutralizes interleukin-13 (IL-13). Atopic dermatitis: 12+ (> 40 lbs) ________ This podcast is made in partnership with The Allergy & Asthma Network. Thanks to Sanofi-Regeneron for sponsoring today's episode. While they support the show, all opinions are our own, and sponsorship doesn't influence our content or editorial decisions. Any mention of brands is for informational purposes and not an endorsement. Disclaimer: This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Join us as we go through the JEADV Editor's Picks of August 2024: (1) One is not born, but becomes a female academic dermatologist (2) Decoding public emotional response to patients with facial acne (3) Atopic dermatitis on the web: evidence is one click away (4) Beware of the hottentota kiss   Read the Editor's Picks here: https://onlinelibrary.wiley.com/doi/10.1111/jdv.20169   Link to video version: https://youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1&si=FEwX-Otytpxs7Ab3   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/  

If you're suffering from atopic dermatitis, the condition isn't just skin deep. Every itch can cascade into a world of discomfort and pain. Every flare up is an interruption to your quality of life, and every scar can leave you feeling less confident. This is a reality millions live in, and often it leads to anxiety and depression, which can exacerbate the skin irritation further.   That's why the condition has to be treated holistically. It's not just about dealing with itchy and inflamed skin. It's about addressing all the ways it affects someone's entire life.   The good news is, we're living in the golden age of atopic dermatitis therapies, and people can get what they need to manage the condition and put it into remission. What causes atopic dermatitis? How can we use lifestyle factors to manage it better?   Why is it critical for physicians to understand the different manifestations of skin conditions in different skin colors? In this episode, I'm joined by board-certified dermatologist and founder of Above & Beyond Dermatology, Dr. Stephen Lewellis. We talk about how to improve your quality of life if you're dealing with atopic dermatitis, and all the interventions and solutions that are available.   If you have a higher risk of atopic dermatitis, stress, irritants and changes in weather are all factors that raise the score of it expressing on your skin. If we can lower the morbidity threshold, that can manage the condition.  -Dr. Stephen Lewellis    Three Things You'll Learn In This Episode   -The root cause of atopic dermatitis Atopic dermatitis is the most common skin disease in the world. What makes someone more prone to it and what triggers flare ups?   -Remission not cure In oncology, we talk about getting cancer into remission. Could changing our language on atopic dermatitis to management serve people better than talking about a cure?    -Don't sound like a textbook Physicians have to get better at talking about atopic dermatitis so that they educate patients and provide solutions.   Guest Bio   Dr. Stephen Lewellis is a board-certified dermatologist and founder of Above & Beyond Dermatology, an integrative dermatology practice that runs on trust, transparency, accountability, and good old fashioned hospitality. Dr. Stephen Lewellis also hosts The Direct Care Derm podcast and writes the Above & Beyond Dermatology newsletter. For more information, head to https://lewellismd.com/ or connect with Dr. Lewellis on LinkedIn.

Dr Linda Stein Gold and Dr Jonathan Silverberg discuss the epidemiology, clinical presentation, and classification of atopic dermatitis of the hand and feet as well the as quantifying the multidimensional burden it has on patients' quality of life in clinical practice. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Dr Jonathan Silverberg: Honoraria as a consultant and/or advisory board member for AbbVie, Alamar, Aldena Therapeutics, Amgen, AOBiome, Apollo Pharma, Arcutis, Arena Pharmaceuticals, Asana, ASLAN Pharmaceuticals, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GSK, Incyte, Invea, Kiniksa, LEO Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, Target RWE, Teva, UNION, and UpToDate. Speaker for AbbVie, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi-Genzyme. Institution received grants from Galderma, Incyte, and Pfizer. Dr Linda Stein Gold: Investigator/advisor and/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Incyte, LEO Pharma, Pfizer, Regeneron, and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2400314 - 1.0 - 06/2024  MAT-US-2405589 v1.0 - P Exp Date: 06/04/2026

As a clinician you likely don't get too excited about an infant with atopic dermatitis, you see it all the time, it's one of the most common skin conditions in infants and children after all. But for a parent, that itchy child really needs your help. Learn how to explain the diagnoses. Stay tuned. ¡Bienvenidos! Welcome to Medical Spanish for Pediatric providers. ¡Vamos! Let's go! Atopic dermatitis is a chronic, relapsing, itchy skin condition. La dermatitis atópico es crónica, reincidente, condición de piel con comezón. It causes inflammation of the skin. Causa inflamación de la piel. The skin becomes red, dry and scaly. La piel se pone roja, seca y escamosa. Typically, it's worse during the cold winter months, and better in the warm summer months. Típicamente, empeora en los meses fríos del invierno, y mejora durante el calor de verano. Don't stop here, learn to talk about the causes and how to treat atopic dermatitis in the extended lesson. Click the link in the show notes or check out the website; www.pediatricmedspanish.com. If you are enjoying this podcast, be sure to leave me 5 stars and write a comment, it helps get the podcast exposure. Thank you so much for your support! ¡Hasta Luego! CLICK HERE for the Extended Lesson: Atopic Dermatitis Disclaimer: this program is not meant to teach medicine or give medical advice, if you or someone you know is in need of medical care, please visit your assigned medical provider.

In this episode, host Dr. Doug Reh speaks with Dr. Justin Turner. They discuss his recently published article: Inflammatory characteristics of central compartment atopic disease. Read the article in the International Forum of Allergy and Rhinology. Listen and subscribe for free on Apple Podcasts , Google Podcasts and Subscribe on Android.

Atopic conditions and environmental factors with Dr. Ian Myles - Risk factors for atopy - Second intention? More like second INFECTION! Want to donate to the cause? Do so here! http://www.uofuhealth.org/dermasphere - Check out our video content on YouTube: https://www.youtube.com/@dermaspherepodcast and VuMedi!: https://www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: https://physicians.utah.edu/echo/dermatology-primarycare - Connect with us! - Web: https://dermaspherepodcast.com/ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: https://www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! https://healthcare.utah.edu/dermatology/skincast/ Luke and Michelle report no significant conflicts of interest... BUT check out our friends at: - Kikoxp.com (a social platform for doctors to share knowledge) - https://www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!)

CME credits: 1.00 Valid until: 24-05-2024 Claim your CME credit at https://reachmd.com/programs/cme/targeting-il-13-in-moderate-to-severe-atopic-dermatitis-forging-a-new-path-to-improved-disease-and-patient-outcomes/16384/ Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel and more effective treatment options have been approved, including those targeting interleukin (IL)-13. Tune in to watch this webcast on incorporating these agents to optimize care for patients with moderate to severe AD with Terry Faleye, Dermatology Physician Assistant at DermSurgery Associates in Houston, Texas, and Dr. Jonathan Silverberg, Professor, Director of Clinical Research, and Director of Patch Testing at George Washington University School of Medicine and Health Sciences in Washington, DC.=

Go online to PeerView.com/DRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease. Upon completion of this activity, participants should be better able to: Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction; Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy; and Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares.

Go online to PeerView.com/DRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease. Upon completion of this activity, participants should be better able to: Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction; Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy; and Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares.

Go online to PeerView.com/DRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease. Upon completion of this activity, participants should be better able to: Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction; Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy; and Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares.

Go online to PeerView.com/DRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease. Upon completion of this activity, participants should be better able to: Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction; Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy; and Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares.

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we are again joined by Dr. Vivian Hernandez-Trujillo from Nicklaus Children's Hospital and will be reviewing the July-Aug 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today's speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Hernandez-Trujillo:  Speaker Takeda, CSL Advisory boards Takeda, Regeneron, Sanofi Consultant  Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

CME credits: 1.50 Valid until: 05-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/improving-management-of-atopic-dermatitis-in-children-and-adults-with-novel-therapies/16084/ Atopic dermatitis (AD) affects people of all ages, races, and ethnicities. Fortunately, treatment options for AD are expanding. This webcast series focuses on emerging therapies, the transition from pediatric to adult care, and combating healthcare disparities from expert perspectives.=

A 60 year-old man who has a 10 year history of Parkinson disease presents with a chief complaint of “flaking skin that just does not go away, sometimes worse, sometimes better”, stating this problem has been present for > 6 years. Concurrent health issues include HTN, dyslipidemia and generalized anxiety disorder. The affected areas are occasionally itchy and will ache when particularly severe. He has used OTC hydrocortisone cream and skin moisturizers without seeing improvement. Physical exam reveals inflamed patches on the scalp, accompanied by greasy yellow scales. Similar lesions are noted in the nasolabial folds and behind the ears and into the ear canals. Which of the following is the most likely diagnosis?A. DandruffB. Seborrheic dermatitisC. PsoriasisD. Atopic dermatitis---YouTube: https://www.youtube.com/watch?v=VgCO_kpY208&list=PLf0PFEPBXfq592b5zCthlxSNIEM-H-EtD&index=39Visit fhea.com to learn more!

Atopic dermatitis, also known as AD, is the most common type of eczema and can show up as itchy, dry and patchy skin. As the season changes, an autoimmune response can be triggered and spark a flare-up. If you have an adolescent who has been diagnosed with this condition, there are a few ways you can help manage it ahead of the fall season. 

Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes that contribute to the development of AD. In addition, they explore individualizing treatment for patients with moderate to severe AD, with a goal of minimizing and preventing flares. Upon completion of this activity, participants should be better able to: Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease; Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy; and Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares

Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes that contribute to the development of AD. In addition, they explore individualizing treatment for patients with moderate to severe AD, with a goal of minimizing and preventing flares. Upon completion of this activity, participants should be better able to: Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease; Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy; and Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares

Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes that contribute to the development of AD. In addition, they explore individualizing treatment for patients with moderate to severe AD, with a goal of minimizing and preventing flares. Upon completion of this activity, participants should be better able to: Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease; Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy; and Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares

Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes that contribute to the development of AD. In addition, they explore individualizing treatment for patients with moderate to severe AD, with a goal of minimizing and preventing flares. Upon completion of this activity, participants should be better able to: Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease; Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy; and Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares

Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes that contribute to the development of AD. In addition, they explore individualizing treatment for patients with moderate to severe AD, with a goal of minimizing and preventing flares. Upon completion of this activity, participants should be better able to: Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease; Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy; and Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares

Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes that contribute to the development of AD. In addition, they explore individualizing treatment for patients with moderate to severe AD, with a goal of minimizing and preventing flares. Upon completion of this activity, participants should be better able to: Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease; Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy; and Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares

Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes that contribute to the development of AD. In addition, they explore individualizing treatment for patients with moderate to severe AD, with a goal of minimizing and preventing flares. Upon completion of this activity, participants should be better able to: Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease; Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy; and Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares

Atopic dermatitis should be viewed as a syndrome rather than a singular disease. Between genetics, skin barrier, environment, microbiome, TH2 immunity, etc. there are so many factors that play a role which is why dermatologists always mention a multimodal approach.Check out more details on this week's episode of The Derm Vet podcast!

In this Audio Summary, Bonnie looks at whether lokivetmab is more effective than oclacitinib in reducing the Canine Atopic Dermatitis Lesion Index score (or some other recognised scoring system), in dogs with atopic skin disease. Read the full Knowledge Summary here.  Audio Summaries are a free resource that enable vets and vet nurses to more quickly and more easily access and digest relevant and up-to-date evidence! A time-saving way to make better and faster evidence-based decisions.

Michela Starace, Department of Medical and Surgical Sciences, University of Bologna, Italy, joins Jonathan to discuss hair loss and its impact on the lives of patients. They also explore how symptoms of conditions can present in nails, and how to treat benign nail tumours. Use the following timestamps to navigate the topics discussed in this episode: (00:00)-Introduction (01:53)-What led Starace into medicine, and the field of dermatology (03:20)-Alopecia areata, the role of JAK inhibitors, and adverse treatment events (06:40)-Commonality of alopecia areata, and its recent reclassification as an autoimmune disease (07:35)-Health-related quality of life and psychosocial anxiety in patients with hair loss (10:03)-Recommendations for the treatment of female androgenetic alopecia (12:03)-The role of trichoscopy in diagnostics (14:36)-Onychoscopy in the diagnosis of nail disorders (17:58)-The International Nail Society's hopes for the future (19:00)-Atopic dermatitis in adolescents (20:08)-Presentation and treatment of benign nail unit tumours (23:32)-Doctor-patient relationship in dermatology (25:23)-Innovations in the field (26:57)-Three wishes for the future of healthcare

Please visit answersincme.com/ZDW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses atopic hand and foot dermatitis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in moderate-to-severe atopic hand and foot dermatitis; Explain how novel systemic agents could address unmet needs for patients with uncontrolled moderate-to-severe atopic hand and foot dermatitis; and Outline future treatment considerations to optimize the use of novel systemic therapies in patients with moderate-to-severe atopic hand and foot dermatitis.

Please visit answersincme.com/ZDW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses atopic hand and foot dermatitis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in moderate-to-severe atopic hand and foot dermatitis; Explain how novel systemic agents could address unmet needs for patients with uncontrolled moderate-to-severe atopic hand and foot dermatitis; and Outline future treatment considerations to optimize the use of novel systemic therapies in patients with moderate-to-severe atopic hand and foot dermatitis.

Is there a difference between intradermal and serum testing for atopic dermatitis? Learn the differences in what these tests measure and why testing should be recommended to your patients on this week's episode of The Derm Vet podcast!

Are allergies getting worse? And does this affect the gut? In this episode, Dr. K walks us through how to spot an atopic cause of gut symptoms and how to test for this. We also dive in to the histamine connection with food sensitivities. And who doesn't love a good debate on food sensitivities?! This is a 2-part series so stay tuned for the next episode on treatment strategies! Topics covered in this episode: - Recognizing an atopy/gut correlation in our patients - Common symptoms - both digestive and systemic - Blood testing for food and environmental allergens - When to refer to an allergist - Histamine diet? Yea or Nay. - ... and a little detour into allergic vaginitis

Atopic dermatitis may not be the most glamorous topic in medicine, but you've got an enormous opportunity to change lives for the better in primary care.It can feel frustrating for both the patients and providers when they keep coming back without getting any better.I got to chat with a pediatric dermatologist and added a TON of clinical pearls to my arsenal of "real world" NP knowledge-- which I'm sharing with you in this week's video.You'll learn:What treatment ACTUALLY works, especially when they've told you they've "tried everything"What skincare to recommend, which steroids, and what unconventional treatments can help keep flares at bayAnswers to popular questions these days: who actually need food allergy testing, to bathe or not to bathe, and more.Download the cheat sheet here: https://www.realworldnp.com/pl/237660Read the full blog post here._______________________________© 2022 Real World NP. For educational and informational purposes only, see realworldnp.com/disclaimer for full details. Hosted on Acast. See acast.com/privacy for more information.

In this VETgirl online veterinary continuing education podcast, we interview Dr. Alice Jeromin, DACVD on atopy in cats, which has since been renamed Feline Atopic Skin Syndrome (FASS). Are you missing the diagnosis of atopy in cats? Find out what the clinical signs of atopy are in cats, what signalment, age and breed gets it, and most importantly, how to treat Feline Atopic Skin Syndrome in your feline patients!

Go online to PeerView.com/RBZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis is a chronically relapsing skin disease that often begins in early childhood and can persist into adulthood, having a detrimental effect on the lives of patients and their families throughout the lifespan. In this activity, based on a recent live web broadcast, our global experts provide both pediatric and adult dermatologists, allergy/immunology specialists, and other specialty advanced practice providers around the world greater insight into the assessment of disease severity, the use of targeted biologic therapy, and the importance of patient engagement and shared decision-making in the management of atopic dermatitis. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD); Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines; Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy; Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care

Go online to PeerView.com/RBZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis is a chronically relapsing skin disease that often begins in early childhood and can persist into adulthood, having a detrimental effect on the lives of patients and their families throughout the lifespan. In this activity, based on a recent live web broadcast, our global experts provide both pediatric and adult dermatologists, allergy/immunology specialists, and other specialty advanced practice providers around the world greater insight into the assessment of disease severity, the use of targeted biologic therapy, and the importance of patient engagement and shared decision-making in the management of atopic dermatitis. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD); Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines; Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy; Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care

Go online to PeerView.com/RBZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis is a chronically relapsing skin disease that often begins in early childhood and can persist into adulthood, having a detrimental effect on the lives of patients and their families throughout the lifespan. In this activity, based on a recent live web broadcast, our global experts provide both pediatric and adult dermatologists, allergy/immunology specialists, and other specialty advanced practice providers around the world greater insight into the assessment of disease severity, the use of targeted biologic therapy, and the importance of patient engagement and shared decision-making in the management of atopic dermatitis. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD); Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines; Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy; Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care

Atopic dermatitis (AD), or atopic eczema -- the most common chronic inflammatory skin disease -- is characterized by intense itching, dry skin and inflammation on any part of the body.1,2While data on the prevalence of AD in adult skin of color (SOC) populations is limited, in patients 17 and under in the U.S., the prevalence of AD is higher among African Americans, at almost 20%, compared with European Americans (16%) and Hispanic Americans (8%).3There has been limited representation of people with SOC in AD clinical studies. People with SOC may present with unique symptoms, such as skin trauma, irritation or inflammation that causes a change in skin color known as post-inflammatory hyper- and hypopigmentation. In hypopigmentation, affected patches of skin become lighter than a patient's normal skin tone. Hyperpigmentation causes the opposite reaction, turning patches of skin darker than normal skin tone. Unfortunately, diverse representation in clinical trials has been limited and current clinical measurement scales can vastly underestimate the severity of AD in people with diverse skin tones. This week, Lotus Mallbris, Ph.D., M.D., is joined by Renata Gontijo Lima, M.D., as well as Lillian, an African American woman living with AD. The group discusses the impact of AD – particularly in people with SOC – and the steps Lilly is taking to generate new disease information to aid investigators and clinicians in providing diagnoses and treatment options for all skin tones. Learn more about Lilly's AD research efforts.References1 Weidinger S, Novak N. Lancet. 2016;387:1109-1122.2 Bieber, T. Nat Rev Drug Discov 21, 21–40 (2022). https://doi.org/10.1038/s41573-021-00266-6.3 Fu T, et al. Pediatr Dermatol. 2014 Jan-Feb;31(1):21-6. doi: 10.1111/pde.12237.

Eczema is a general term for rash-like skin conditions with atopic dermatitis being the most common form. Atopic dermatitis is a chronic inflammatory skin disease characterised by itching and recurrent eczema patches. Up to 20 percent of children can be affected by atopic dermatitis, but even in adults, it is far from uncommon with prevalence rates of between 1 and 3 percent. One growing area of study in the cause and treatment of atopic dermatitis is the role of the gut and skin microbiome through its effects on our immune system. One area of interest is the role of probiotics in treating eczema. And while much of the research here has been on infants and children, there has been a growing evidence base for adults as well. And that's what I'll be exploring in this podcast.Links referred to in the podcastSystematic review of probiotics in adults with atopic dermatitis https://pubmed.ncbi.nlm.nih.gov/35670101Episode transcriptTo access the full episode transcript, go to the following link and select the individual podcast episode and then click on the ‘Transcript' tab https://thinkingnutrition.buzzsprout.comConnect with meInstagram: doctimcroweFacebook: Thinking NutritionTwitter: CroweTim

As a dermatology specialists we tend to see the more severe, chronic cases of allergic dermatitis and infection. But in general practice, our colleagues are seeing these cases at much earlier stage in younger dogs. So how do you start management at these initial signs of allergies?This podcast episode welcomes back Dr. Dana Liska, DACVD. Dr. Liska is a senior veterinary dermatologist with Zoetis. We discuss early recognition, management and client communication regarding canine allergic dermatitis.This podcast is sponsored by Zoetis.

I opened it up on Instagram! In this episode, I answer the top questions submitted regarding canine atopic dermatitis. This is a great summary of some of the most important aspects of this chronic, frustrating disease.

This week on Integrative Wellness Radio we're discussing skin conditions but specifically Eczema. Atopic dermatitis or commonly known as Eczema is a condition that makes your skin red and itchy. It's common in children but can occur at any age. Join Dr. Nicole as she briefs us in-depth on why Eczema is developing at such a young age that it is now being referred to as Baby-Eczema and how this can persist as problematic all the way into adulthood. She walks us through some of the key points why infants are more vulnerable to it and how it affects them in the first place. Tune in to the full episode to learn more about the proper diagnosis, right testing, and prevention when it comes to skin diseases. Interested in working with IWG? Book a complimentary consult call to learn more using this link: https://bit.ly/IWRcall2022  Noteworthy Time Stamps: 02:39 Skin conditions at young ages aren't normal 05:25 It's not your fault that your baby has Eczema 09:32 The location of birth matters when it comes to skin conditions 13:43 A 2-month-old baby's case study 17:41 Toxins found in amniotic fluid 21:45 Are skin conditions affected by birth?   25:06 Ingredients matter in a vaccine  31:06 Antibiotics are made from the mold 36:12 Very rarely do things look like the textbook 41:30 No one test is the gold standard

Welcome Dr. Valerie Fadok, DVM, PhD, DACVD back to the podcast. She is a senior veterinary dermatologist with Zoetis. One of her passions involves a dog breed that we see quite often in dermatology... The West Highland White Terrier aka Westie! Hear all about this allergy prone breed and the amazing research being done through the Westie Foundation of America (westiefoundation.org). Some wonderful studies are mentioned on this episode. The references are listed below:1. Favrot C et al. Atopic dermatitis in West Highland white terriers- part 1: natural history of atopic dermatitis in the first three years of life. Vet Dermatol 2020;301:106-e16. AR-170462. Rostaher A, et al. Atopic dermatitis in a cohort of West Highland white terriers in Switzerland. Part II: estimates of early life factors and heritability. Vet Dermatol 2020; 31:276-e66. AR-170453. Rostaher A, et al. Atopic dermatitis in a cohort of West Highland white terriers in Switzerland. Part III: early life peripheral blood regulatory T cells are reduced in atopic dermatitis. Vet Dermatol 2021; 32:239-e63. AR-17047This podcast was sponsored by Zoetis. Zoetis is dedicated to changing the way we approach canine pruritus to protect the bonds between the pet, the owner and the veterinary team.

Videos: 1. The Truth About Margaret Sanger (2:30) 2. This war on women, men and children is blatant and it has to be exposed! – Rizza Islam (2:23) 3.  Vitamin Authentication. Electronic pill that stays in your body & will become a 18bit Battery operated chip (1:00) 4. Saudi Arabia Joining The BRICS Would Have Huge Repercussions (5:25) 5.  87% of Clinical Trial Data Hidden from Medical Journals; Fmr FDA Director: Not Our Job to Correct Faulty Drug Data in Articles – Roman Balmakov from Matter of Fact  (10:00) Articals: 1. Two and 3-year-old kids with seizures is “the new normal” 2. All 16 Runners Who Collapsed and Runner Who Died at Brooklyn Half Marathon Said They Were Vaccinated Almonds reduce the risk of heart disease, research show Aston University (UK)  June 30, 2022 Scientists have found that eating almonds in your diet can reduce the risk of heart disease by keeping blood vessels healthy. Research found that they significantly increase the amount of antioxidants in the blood stream, reduce blood pressure and improve blood flow. These findings add weight to the theory that Mediterranean diets with lots of nuts have big healthbenefits. Researchers tested the effects of a short-term almond-enriched diet on healthy young and middle-aged men as well as on a group of young men with cardiovascular risk factors including having high blood pressure or being overweight. A control group ate what they normally would, while another group consumed snacks of 50g of almonds a day for one month. At the end of the study period, the group eating an almond-enriched diet had higher levels of antioxidants (alpha-tocopherol) in their blood stream, improved blood flow and lower blood pressure, potentially reducing their risk of heart disease. Taking Vitamin D during pregnancy could lower the risk of eczema in babies University of Southampton (UK), July 6, 2022 Taking Vitamin D supplements during pregnancy could substantially reduce the chances of babies up to a year old suffering from atopic eczema, according to a new study by University of Southampton researchers. The research, published in the British Journal of Dermatology, revealed that babies had a lower risk of developing atopic eczema in their first year if their mothers took 1000 international units (IU) of Vitamin D a day from when they were 14 weeks pregnant until they delivered. The effect was particularly seen in babies who were later breastfed for more than a month. Atopic eczema is a chronic inflammatory condition that can have a large impact on sufferers, their families, and healthcare. It is estimated that one in six children aged one to five has atopic eczema, and there has been a global rise over recent decades. More than 700 pregnant women took part in the research—with 352 taking the supplements from 14 weeks until they gave birth and 351 taking a placebo. “Our results showed that babies of mothers who received supplements had a lower chance of having atopic eczema at 12 months, which supports recommendations for Vitamin D supplements to be routine during pregnancy.” Student of Neuroscience Shows How Meditation may Vanquish Mental Disorders University of Massachusetts Medical School, July 3, 2022   According to theNational Institute of Mental Health (NIMH), 7.7 million Americans suffer from schizophrenia and bipolar disorder – approximately 3.3% of the US population when combined. Of these, approximately 40% of the individuals with schizophrenia and 51% of those with bipolar are untreated in any given year, but with the new studies being presented by Juan Santoyo and his peers, there could be strong scientific proof that meditation could help even the most debilitating psychological disorders. The paper describes how meditation affects a subject's ability to change brain activity in the posterior cingulate cortex (PCC). Given the chance to observe real-time feedback on their PCC activity, some meditators were even able to control the levels of activity there. “You can observe both of these phenomena together and discover how they are co-determining one another,” Santoyo said. “Within 10 one-minute sessions they [participants in a meditation study] were able to develop certain strategies to evoke a certain experience and use it to drive the signal.” In the study on ‘effortless awareness,' a phenomenon that often accompanies meditation, he noticed that specific memories or thoughts that caused distress could be changed with feedback after a meditation session. Fasting could regenerate the immune system, study say University of Southern California, July 1, 2022 Refraining from food for as little as two days can regenerate the immune system, helping the body to fight infection, according to a new study. Scientists at the University of Southern California said the findings could have major implications for the elderly and people suffering from damaged immune systems, such as cancer patients. Researchers tested the effects of fasting for two to four day periods over the course of six months on both mice and humans.  In both cases, long periods of not eating significantly lowered white blood cell counts. And in mice, each cycle of fasting then “flipped a regenerative switch” that triggered stem cell-based regeneration of new white blood cells, thereby renewing the body's defence system. Valter Longo, Professor of Gerontology and the Biological Sciences at the University of Southern California, said:”It gives the OK for stem cells to go ahead and begin proliferating and rebuild the entire system. “And the good news is that the body got rid of the parts of the system that might be damaged or old, the inefficient parts, during the fasting.” The study also found that fasting reduces levels of the enzyme PKA, an effect which is known to increase longevity in simple organisms, as well as levels of the hormone IGF-1, which has been linked to ageing, tumour progression and cancer risk. In addition, a small pilot clinical trial found that fasting for a 72-hour period prior to chemotherapy protected patients against toxicity. Men with ‘low testosterone' have higher rates of depression George Washington University Medical Center, July 1, 2022 Researchers at the George Washington University (GW), led by Michael S. Irwig, M.D., found that men referred for tertiary care for borderline testosterone levels had much higher rates of depression and depressive symptoms than those of the general population. The research, involved 200 adult men, aged 20-77, with a mean age of 48 years old, who were referred for borderline total testosterone levels between 200 and 350 ng/dL. Depression and/or depressive symptoms were present in 56 percent of the subjects. Furthermore, one quarter of the men in the study were taking antidepressants and that the men had high rates of obesity and low rates of physical activity. The most common symptoms were erectile dysfunction, decreased libido, fewer morning erections, low energy, and sleep disturbances. While more research is needed in this area of study, the researchers concluded that clinicians should consider screening for depression and depressive symptoms, overweight and unhealthy lifestyle factors in men who are referred for tertiary care for potential hypogonadism. Research shows how breastfeeding offers immune benefits Binghamton University, July 5, 2022 When infants breastfeed, they receive an immune boost that helps them fight off infectious diseases, according to recent research from Binghamton University Associate Professor of Anthropology Katherine Wander. For the project, the research team studied almost 100 mother and baby pairs in rural Kilimanjaro. Prolonged breastfeeding is the norm in this population and infectious diseases during infancy are very common, even compared to other areas of East Africa. This makes Kilimanjaro an ideal setting to begin to understand how immune protection from milk might affect infectious disease risk, Wander said. “You most often hear about the immune system of milk in terms of transferring maternal antibodies to infants via milk—which is probably very important—but it seems there's much more going on as well. The immune system of milk is a whole system, capable of mounting immune responses,” Wander said. “We're only beginning to understand the full extent and role of the immune system of milk.” To test the impact of milk's immune system on infant health, the researchers combined a few milliliters of milk with a small amount of bacteria, then placed the mixture in an incubator overnight. They then measured the increase of interleukin-6, an immune cell communication molecule that promotes inflammation. This in-vitro response gives an indication of how the milk's immune system is likely to respond to bacteria encountered in the infant's body—the gut, for example. The research team also followed the Tanzanian infants to assess whether those who received milk that mounted stronger immune responses during the in-vitro tests were at lower risk for infectious diseases. That appeared to be the case: infants whose mothers' milk mounted larger responses to Salmonella had fewer infectious diseases, particularly respiratory infections such as pneumonia.

This is the first episode of our 5 part series in collaboration with the Allergy & Asthma Network about atopic dermatitis in skin of color.  In the first episode, we are going to talk about atopic dermatitis (AD) in people with skin of color. Atopic dermatitis affects everyone differently, which means it does not look the same on everyone or in every skin color. It is important to recognize this and to raise awareness on how AD impacts certain populations differently than others.  Along with Kortney, Dr. G will be sharing her expertise as an allergist and will be overviewing the basics of AD. Special guest Shiv Sewlal shares her personal experiences with atopic dermatitis.    What we cover in this episode • Why are we doing a podcast series about atopic dermatitis (AD) in people with skin of color? • What is atopic dermatitis? • Is eczema the same thing as atopic dermatitis? • What is the difference between child onset versus adult-onset atopic dermatitis? Can you develop AD as an adult? • Why is atopic dermatitis more prominent in people with skin of color? • How can housing impact your skin?  • Why air conditioning can be helpful for people with atopic dermatitis. • Why is atopic dermatitis underdiagnosed in patients with skin of color? • What are the symptoms of AD in different skin colors? • What are triggers? How do these make atopic dermatitis worse? • How does mental health impact atopic dermatitis? • What is the itch-scratch cycle? • Who should you see if you think you have atopic dermatitis?   From Shiv • Shiv shares what her atopic dermatitis looks like • Shiv and her mom's experience with therapy to help with her skincare   Helpful Resources •  All our past atopic dermatitis episodes: https://www.itchpodcast.com/eczema • More about Shiv: https://www.instagram.com/shivaika/ • "What is eczema" from Allergy & Asthma Network: https://allergyasthmanetwork.org/what-is-eczema/

In this episode, Dr. Lisa and Dr. Toni discuss the atopic triad of allergy, asthma and eczema that both perimenopausal moms and their kids can experience. Find out how your hormones are involved, plus what you can do to prevent and treat these inflammatory issues today. The post Episode 125 – Atopic Triad: Allergy, Asthma and Eczema in Moms and Kids appeared first on The Perimenopausal Mamas Podcast.